Material-Sparing Formulation Strategies For Enhancing Bioavailability Of Challenging Beyond Rule Of Five (bRo5) Molecules

A small pharmaceutical company collaborated with Catalent to overcome the complex challenges of formulating a poorly soluble, beyond rule of five (bRo5) small molecule classified as DCS IIb. Leveraging deep expertise in intestinal mass transport, Catalent conducted a mechanistic study to address permeability limitations, using sodium taurocholate/lecithin micelles and bile salt solutions to simulate in vivo conditions.

By applying a material-sparing, biorelevant in vitro membrane flux assay, Catalent designed scalable prototype formulations aimed at enhancing bioavailability. These prototypes were then provided to the client for in vivo pharmacokinetic (PK) studies, which confirmed improved absorption and validated the formulation strategy. This collaboration demonstrates how advanced scientific approaches, combined with practical, resource-efficient methodologies, can enable emerging pharmaceutical companies to overcome formulation challenges and accelerate development, even with limited internal resources.